Business
Cannabics Pharmaceuticals Files Patent Application for the Company's Slow Release Capsules
Cannabics Pharmaceuticals Files Patent Application for the Company's Slow Release Capsules.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Files Patent Application for the Company's Slow Release Capsules\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Files Patent Application for the Company's Slow Release Capsules\nPR Newswire\nBETHESDA, Md., Feb. 24, 2016\n\n\n\nBETHESDA, Md., Feb. 24, 2016 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an exclusive provisional patent application with the US Patent & Trademark Office (USPTO) on a wholly new scheme of technology for implementation of the company's Slow Release technology for medical capsules. \n\n\nCreating a natural therapy for cancer patients has become the main focus of Cannabics Pharmaceuticals R&D branch. The clinical data now being collected as well as their scientific research are targeted for the development of personalized anti-cancer treatments.\n\nDr. Eyal Ballan, Chief Scientist of the company remarked \"This is a great opportunity to uncover the potential therapeutics of multifactorial compounds and design scientifically advanced yet natural medicine.\"\n\nAbout Cannabics Pharmaceuticals Inc.\n\nCannabics Pharmaceuticals (CNBX), a U.S based company, is dedicated to the development of Palliative and personalized Anti-Cancer treatments. The Company's scientific focus is on harnessing the therapeutic properties of natural Cannabinoids. Cannabics' vision is to create tailored therapies for cancer patients, utilizing advanced screening systems and bioinformatic tools. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health and involves both scientific and academic research as well as current medical clinical studies\n\nDisclaimer:\n\nCertain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as \"believes,\" \"expects,\" \"anticipates,\" \"estimates,\" \"intends,\" \"plans,\" \"targets,\" \"projects\" and similar expression...